Australian clinical stage drug development company, Noxopharm Limited (ASX:NOX), provides to shareholders and the market generally the attached corporate presentation ahead of a series of global virtual investor presentations during late February/March 2021.
The document titled, “Updated Corporate Presentation February- March 2021”, provides an updated overview of the Company’s clinical programs with a focus on the important LuPIN trial data recently announced at the recent 2021 ASCO Genitourinary Cancers Symposium and the imminent start of the IONIC study, testing the ability of Veyonda® to overcome resistance to the immune checkpoint inhibitor, nivolumab (Bristol Myers Squibb).
For more information, download the attached PDF.
Download this document
